×
NewsCAP: American Society of Hematology guidelines issued for VTE.
https://doi.org/10.1097/01.NAJ.0000554019.98098.07
The American Journal of Nursing;

Feb 24th, 2019 - NewsCAP: American Society of Hematology guidelines issued for VTE.|2019||

VTE Prophylaxis for High-Risk Ambulatory Cancer Patients?
https://www.medscape.com/viewarticle/909543

Feb 24th, 2019 - The use of direct oral anticoagulants for the prevention of venous thromboembolism (VTE) in high-risk ambulatory cancer patients showed promising results in two clinical trials published online in the New England Journal of Medicine February 21. The findings present a possible new population of cancer patients who may benefit from thromboprophylaxis. Currently, such prophylaxis is recommended f...

Luspatercept May Reduce the Need for Transfusion in Lower-Risk Myelodysplastic Syndromes
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/luspatercept-may-reduce-the-need-for-transfusion-in-lower-risk-myelodysplastic-syndromes/

Feb 24th, 2019 - IN THE RANDOMIZED, double-blind, phase III MEDALIST trial, the experimental drug luspatercept significantly reduced the need for frequent red blood cell transfusions in patients with lower-risk myelodysplastic syndromes (MDS) and ring sideroblasts. With luspatercept, 37.8% of patients remained transfusion-free for 8 weeks or longer, compared with 13.2% of patients who received a placebo, report...

Conference Highlights From the 2018 American Society of Hematology Annual Meeting & Exposition
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/conference-highlights/

Feb 24th, 2019 - A Vista of Scientific and Clinical Advances Krishna Gundabolu, MBBS In sunny San Diego, the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition welcomed nearly 30,000 attendees who were eager to present, learn, network, and cheer the joint achievements of many researchers. The packed meeting was filled with important information from thousands of investigators presenting their...

PAUSE Study Establishes Simple Approach to Perioperative Management of Direct Oral Anticoagulants
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/pause-study-establishes-simple-approach-to-perioperative-management-of-direct-oral-anticoagulants/

Feb 24th, 2019 - The largest study to date addressing the common problem of perioperative direct oral anticoagulant (DOAC) management has shown that patients with atrial fibrillation can safely stop taking their anticoagulant for 1 day before and after procedures with a low risk of bleeding and for 2 days before and after procedures with a higher bleeding risk, according to data presented at the 2018 American S...

Pilot Study Tests Novel Approach to Gene Therapy for Sickle Cell Disease
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/pilot-study-tests-novel-approach-to-gene-therapy-for-sickle-cell-disease/

Feb 24th, 2019 - Initial findings from a first-in-human trial have provided proof of principle for a groundbreaking approach to gene therapy for sickle cell disease, according to data presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Erica B. Esrick, MD Early results of genetic targeting of the fetal-to-adult globin switch showed effective collection, gene modification, an...

Newly Discovered Mutation in BCL2 Protein Impacts Outcomes in Patients With Progressive CLL
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/mutation-in-bcl2-protein-impacts-outcomes-in-patients-with-progressive-cll/

Feb 24th, 2019 - INVESTIGATORS FROM Australia have identified a genetic mutation that causes resistance to the targeted drug venetoclax in patients with chronic lymphocytic leukemia (CLL), according to research presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition1 and simultaneously published in Cancer Discovery.2 Piers Blombery, MD, of the Peter MacCallum Cancer Centre and Roy...

Crizanlizumab Improves Prevention of Vaso-occlusive Crises in Patients With Sickle Cell Disease
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/crizanlizumab-improves-prevention-of-vaso-occlusive-crises-in-patients-with-sickle-cell-disease/

Feb 24th, 2019 - For the first time in more than 20 years, patients with sickle cell disease may have another treatment option to reduce painful vaso-occlusive crises, according to data presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Results of the phase II, randomized, double-blind, placebo-controlled SUSTAIN study published this past year showed that crizanlizumab (adm...

Front-Line Ibrutinib Improves Progression-Free Survival in Older Patients With Chronic Lymphocytic Leukemia
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/front-line-ibrutinib-improves-progression-free-survival-in-older-patients-with-cll/

Feb 24th, 2019 - IN A PHASE III TRIAL reported during the Plenary Session at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition and published in The New England Journal of Medicine, single-agent ibrutinib and ibrutinib/rituximab were associated with superior progression-free survival vs chemoimmunotherapy with rituximab/bendamustine among patients 65 years and older with untreated chronic...

First-Line Ibrutinib/Rituximab Combination Shows Benefit for Younger Patients With CLL
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/first-line-ibrutinibrituximab-combination-shows-benefit-for-younger-patients-with-cll/

Feb 24th, 2019 - FIRST-LINE therapy with the combination of ibrutinib and rituximab reduced disease progression by two-thirds compared with standard chemotherapy using fludarabine, cyclophosphamide, and rituximab (FCR) in younger patients with chronic lymphocytic leukemia (CLL), according to the late-breaking results of the ECOG-ACRIN E1912 trial presented at the 2018 American Society of Hematology (ASH) Annual...

Large Single-Arm Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/hydroxyurea-for-sickle-cell-anemia-in-sub-saharan-africa/

Feb 24th, 2019 - Leon Tshilolo, MD, PhD, discusses the plenary abstract on improving sickle cell disease outcomes in the United States and Africa. Photo by © ASH/Todd Buchanan 2018. THE LARGEST PROSPECTIVE trial of hydroxyurea for sickle cell anemia has shown that this treatment is feasible, accepted, well tolerated, and safe for children living in sub-Saharan Africa. Hydroxyurea has long been the standard of c...

Low-Dose Rituximab Effective for Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/low-dose-rituximab-effective-for-acquired-thrombotic-thrombocytopenic-purpura-with-severe-adamts13-deficiency/

Feb 24th, 2019 - The results of a recent pilot study suggest that low-dose rituximab provides similar efficacy to standard-dose rituximab for the treatment of acquired thrombotic thrombocytopenic purpura (TTP), a finding that could point to potential cost savings for patients in the nonlymphoma setting. According to data presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition,1 ad...

Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Outcomes From the MAIA Trial
https://ascopost.com/issues/february-25-2019-supplement-conference-highlights-ash-2018/daratumumab-lenalidomide-and-dexamethasone-in-patients-with-newly-diagnosed-multiple-myeloma-outcomes-from-the-maia-trial/

Feb 24th, 2019 - Thierry Facon, MD, speaks to the press about abstract LBA2 during a press briefing. Photo by © ASH/Luke Franke 2018 In patients with newly diagnosed multiple myeloma who are not eligible for stem cell transplantation, the addition of daratumumab to lenalidomide and dexamethasone significantly reduced the risk of death or disease progression by 44%, according to a late-breaking abstract presenta...

Highlights From the 2018 ASH Annual Meeting & Exposition
https://ascopost.com/issues/february-25-2019/highlights-from-the-2018-ash-annual-meeting-exposition/

Feb 24th, 2019 - TO ADD to our ongoing coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, we bring readers of The ASCO Post these summaries of an assortment of interesting studies. They focus on novel therapies under investigation in the treatment of acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), multiple myeloma, diffuse large B-cell lymphoma (DLBCL), a...

Update on FDA-Approved CAR T-Cell Products
https://ascopost.com/issues/february-25-2019/update-on-fda-approved-car-t-cell-products-axicabtagene-ciloleucel/

Feb 24th, 2019 - Part 2: Axicabtagene Ciloleucel AXICABTAGENE CILOLEUCEL (also known as CAR19) is an anti-CD19 chimeric antigen receptor (CAR) T-cell product approved by U.S. Food and Drug Administration to treat selected hematologic malignancies.1 To appreciate the clinical trial findings summarized here, from selected abstracts presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposi...

Final ‘Vision’ report addresses MOC woes
https://www.mdedge.com/neurology/article/195009/practice-management/final-vision-report-addresses-moc-woes/page/0/2?channel=39313

Feb 23rd, 2019 - The commission’s final report incorporates a number of changes that physicians offered based on a draft version of the report. The American College of Physicians commented that it “objects to the use of data regarding quality measures for individual diplomate certification status, because physician-level measures of quality are flawed, and because physician-level data inevitably leads to physic.

Society guideline links: Thrombotic microangiopathies (eg, TTP and HUS)
https://www.uptodate.com//contents/society-guideline-links-thrombotic-microangiopathies-eg-ttp-and-hus

Introduction This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines. The recommendations in the following guidelines may vary from those...

ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patients
https://www.mdedge.com/cardiology/article/194780/thrombosis/icymi-rivaroxaban-reduces-vte-incidence-ambulatory-cancer?channel=48440
Lucas Franki

Feb 20th, 2019 - While treatment with rivaroxaban did not significantly reduce venous thromboembolism incidence in high-risk ambulatory patients with cancer over the entire course of a 180-day intervention period (6. 0% vs.

FDA approves turoctocog alfa pegol for hemophilia A
https://www.mdedge.com/hematology-oncology/article/194761/bleeding-disorders/fda-approves-turoctocog-alfa-pegol-hemophilia?channel=39313
Jennifer Smith

Feb 20th, 2019 - The Food and Drug Administration has approved turoctocog alfa pegol (N8-GP, Esperoct), a glycopegylated recombinant factor VIII product, to treat hemophilia A. The agency approved turoctocog alfa pegol for use as routine prophylaxis to reduce the frequency of bleeding episodes, for on-demand treatment and control of bleeding episodes, and for perioperative management of bleeding in adults and c.

Structured decision-making drives guidelines panels' recommendations "for" but not "aga...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268742
Journal of Clinical Epidemiology; Djulbegovic B, Reljic T et. al.

Feb 19th, 2019 - The determinants of guideline panels' recommendations remain uncertain. The objective of this study was to investigate factors considered by members of 8 panels convened by the American Society of Hematology (ASH) to develop guidelines using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Web-based survey of the participants in the ASH guidelines panels. two-l...